Watch Ticker

Amicus Therapeutics, Inc

Go to Amicus Therapeutics, Inc Website

$6.99

0.00 (0.00%)

Live

Previous Close

$6.99

Day Range

$0 - $0

Previous Day Range

$6.74 - $7.0393

Market Cap

$2.1 billion USD

Day Vol.

Previous Day Vol.

4.6 million

Currency

USD

Primary Exchange

Nasdaq

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to ad...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Amicus Therapeutics - Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

Amicus Therapeutics reported Q2 2025 total revenue of $154.7M, up 18% at constant exchange rates, with strong performance from Galafold and Pombiliti + Opfolda. The company expects to reach GAAP profitability in H2 2025 and anticipates exceeding $1 billion in total revenue by 2028.

Related tickers: FOLD.

Read Full Article

Amicus Therapeutics - New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Amicus Therapeutics announced the publication of a post-hoc analysis of data from the PROPEL study, which showed that patients with late-onset Pompe disease who switched from alglucosidase alfa to cipaglucosidase alfa-atga + miglustat experienced improvements or stability in most outcomes, while those who remained on alglucosidase alfa generally showed worsening or stability.

Related tickers: FOLD.

Read Full Article

Trending Tickers

Please sign in to view